An adjusted Cox proportional hazard analysis revealed a 56% reduced adjusted hazard of death (aHR 0.44, 95% CI: 0.26–0.74, p = 0.002) when add-on VA was added to first-line PD-1/PD-L1 therapy in this subgroup with PD-L1-positive NSCLC; see Figure 4. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.